MIRA MIRA PHARMACTLS
MIRA PHARMACTLS (MIRA) is expected to report earnings on November 11, 2026, before the market open.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About MIRA PHARMACTLS
MIRA Pharmaceuticals Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. MIRA Pharmaceuticals Inc. is based in Baltimore, Maryland.